BrightGene Research Development from 2010 to 2025
| 688166 Stock | 30.92 1.21 4.07% |
Research Development | First Reported 2019-09-30 | Previous Quarter 77.7 M | Current Value 69.6 M | Quarterly Volatility 16.8 M |
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
BrightGene | Research Development |
Currently Active Assets on Macroaxis
Other Information on Investing in BrightGene Stock
BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.